ArticleCancer research communications2025

A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2.

Monica M Mita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.